Prostate cancer is one of the most common malignancies threatening men's health worldwide. With population aging and lifestyle changes, the incidence of prostate cancer in China has been steadily increasing in recent years. As an early-stage disease, localized prostate cancer generally has a favorable prognosis, with curative potential through comprehensive treatment primarily centered on local interventions such as surgery. Enhancing the diagnosis and treatment of localized prostate cancer is key to improving overall survival rates for prostate cancer patients. Looking back at 2024, what were the major research advances in this field? This review will summarize key developments in screening and diagnosis, neoadjuvant therapy, surgical treatment, and the management of biochemical recurrence after surgery.

Breast cancer has become one of the most common malignancies among women, with triple-negative breast cancer (TNBC) being considered the most aggressive subtype due to its historically poor prognosis. Looking back at 2024, significant research breakthroughs have emerged in both early-stage and advanced TNBC treatment, covering chemotherapy, targeted therapy, immunotherapy, and antibody-drug conjugates (ADCs). Many of these studies have been led by Chinese researchers, contributing to original findings in the field. In this annual review, Dr. Qiang Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University shares the key advancements in systemic therapy for TNBC, showcasing how precision medicine is gradually transforming TNBC treatment and offering patients a brighter future.

Bladder cancer is one of the most common malignancies of the urinary system, posing a serious threat to public health in China. For patients with localized disease, repeated intravesical treatments and follow-up procedures require frequent hospital visits, while those who undergo surgery often face the lifelong challenge of urinary diversion. Patients with inoperable advanced bladder cancer also have limited treatment options, as traditional chemotherapy provides only modest benefits. These significant unmet medical needs—affecting both survival and quality of life—have driven continuous innovation in the field of bladder cancer treatment.

At the San Antonio Breast Cancer Symposium (SABCS 2024), Dr. Maria Margarete Karsten and her team presented groundbreaking findings from the PRO B trial, a multicenter study evaluating the impact of alert-based patient-reported outcome (PRO) monitoring in metastatic breast cancer patients.

This study was conducted by Dr. Zhi Peng and his colleagues from Beijing Cancer Hospital, China, in collaboration with Sichuan University, Hunan Cancer Hospital, and Jiangsu Aosaikang Biopharmaceutical Co., Ltd.…

Metastatic colorectal cancer (mCRC) remains a significant clinical challenge, particularly in patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) tumors, which tend to respond poorly to immunotherapy. The AtezoTRIBE phase II…

1. Classification and Current Status of BTC Since 2010, experts have classified intrahepatic cholangiocarcinoma (ICC) as part of BTC and established an independent staging system. According to the 2022 CSCO…

The increasing prevalence of breast cancer among younger women poses significant challenges for early detection and treatment. At the 2024 Yixian Breast Cancer Conference and the 2nd China Young Breast Cancer Consensus Conference, Dr. Anqin Zhang from Guangdong Women and Children’s Hospital provided an in-depth analysis of the current status and issues surrounding breast cancer screening in younger populations. In an interview with Oncology Frontier, Professor Zhang shared insights from his extensive clinical experience and the latest research, addressing the challenges of breast cancer screening for young women, recommending effective screening methods, and proposing strategies to enhance participation and outcomes.